Explore all of our publications and interviews in academic journals and mainstream media using the filter and search functions.
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
The ability to charge high prices is only one component of a complex system of risks and rewards that underlies pharmaceutical innovation.
Medicare Negotiation: A "Too Little" or "Too Late" Framework for Drug Selection
Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.
Abandon Biosimilars as Biologics are Natural Monopolies
Biosimilars will not effectively lower the price of biologic drugs after the period of market exclusivity.
HA Blog 04/15/2019
List Price, Net Price, and the Rebate Caught in the Middle
Pharmacy benefit managers (PBMs), such as Express Scripts, CVS Caremark, and Optum Rx, are some of the larger companies that administer the Medicare Part D prescription drug benefit.
JAMA Viewpoint 03/06/2019
No Results Found